Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease [Yahoo! Finance]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Yahoo! Finance
Hoth is developing this therapeutic in Partnership with the Department of Veterans Affairs Key Findings from the Study: Protection Against High-Fat Diet-Induced Obesity – GDNF-tg mice exhibited significantly lower body weight and reduced fat deposition despite consuming a high-fat diet. Enhanced Fat Burning and Energy Expenditure – GDNF increased basal metabolic rate, oxygen consumption, and carbon dioxide production, leading to higher energy expenditure without changes in food intake. Inhibition of Fat Cell Formation (Adipogenesis) – GDNF suppressed key genes involved in fat storage, including PPAR-?, FASN, and SREBF1, while promoting fat oxidation pathways. Improved Insulin Sensitivity and Glucose Regulation – GDNF-tg mice showed enhanced glucose tolerance and lower serum leptin levels, markers of improved metabolic health. Reduced Fatty Liver Disease – GDNF prevented hepatic steatosis (fat accumulation in the liver), a common obesity-related complication. NEW YORK Ma
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics (NASDAQ:HOTH) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Hoth Therapeutics (NASDAQ:HOTH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.MarketBeat
- Hoth Therapeutics Issues Comprehensive Pipeline Update Highlighting Clinical Progress, Orphan-Designated HT-KIT, Advancing HT-001 Phase 2, and New GDNF Metabolic ProgramPR Newswire
- Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025 [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics to Present at Noble Capital Markets 21st Annual Emerging Growth Equity Conference, December 2-3, 2025PR Newswire
HOTH
Sec Filings
- 12/5/25 - Form EFFECT
- 11/17/25 - Form S-3
- 11/13/25 - Form 424B5
- HOTH's page on the SEC website